ASTRAZEN - Fundamental Analysis: Financial Health & Valuation

📊 Financial Overview: AstraZeneca Pharma India exhibits strong profitability with a ROCE of 33.4% and ROE of 23.6%, indicating efficient capital deployment. The company maintains a conservative debt-to-equity ratio of 0.05, supporting long-term financial resilience. EPS stands at ₹73.3, and quarterly PAT came in at ₹56.1 Cr, slightly down from ₹62.3 Cr, though the YoY profit variance of 60.1% reflects strong growth. The stock is trading above both DMA 50 and DMA 200, suggesting bullish technical momentum.

💰 Valuation Metrics: AstraZeneca trades at a steep P/E of 112, significantly above the industry average of 33.1, indicating premium valuation. The P/B ratio is ~30.84 (₹9,500 / ₹308), and the PEG ratio of 2.60 suggests moderate overvaluation relative to growth. A dividend yield of 0.34% offers minimal income support.

🏢 Business Model & Competitive Edge: AstraZeneca Pharma India is a subsidiary of the global biopharmaceutical giant, focusing on oncology, cardiovascular, and respiratory therapies. Its strong R&D pipeline, brand credibility, and access to global innovations provide a durable competitive edge. The company benefits from rising demand for specialty drugs and chronic disease management, though pricing regulations and patent expiries pose risks.

📉 Entry Zone: A favorable entry zone lies between ₹8,800–₹9,200, near the 50 DMA and below recent highs, offering better valuation comfort.

📈 Long-Term Holding Guidance: AstraZeneca is a suitable long-term hold for investors seeking exposure to high-quality pharma with global backing. Accumulate on dips and monitor regulatory developments, product launches, and R&D milestones.